Canine Acute Pancreatitis: Severity Assessment and Treatment

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-08-11

Key Takeaways

• Canine acute pancreatitis presents a spectrum from mild gastrointestinal upset to severe systemic inflammatory disease with organ dysfunction, necessitating structured severity assessment beyond initial clinical judgment within the first 24 hours.
• Early and aggressive fluid resuscitation with balanced isotonic crystalloids, coupled with frequent monitoring of perfusion parameters (mucous membrane color, CRT, heart rate, blood pressure, urine output) and lactate clearance, is critical for managing hypovolemia and hypoperfusion due to endothelial leak and third-space losses.
• Pain management is paramount, utilizing opioid analgesics as the mainstay, with multimodal approaches (e.g., lidocaine CRI) employed for persistent pain, while non-steroidal anti-inflammatory drugs (NSAIDs) are generally avoided due to renal and gastrointestinal risks.
• Early enteral nutrition, initiated within 24-48 hours via oral feeding, nasoesophageal, or esophagostomy tubes, is favored over historical pancreatic rest to maintain gut barrier integrity and improve outcomes, with parenteral nutrition reserved for cases intolerant to all enteral routes.
• Severity assessment relies on a combination of clinical and clinicopathologic markers (leukocytosis/leukopenia, azotemia, hyperglycemia, hypocalcemia, elevated D-dimer) and serial monitoring of perfusion, coagulation, and renal function, guiding escalation or de-escalation of therapy.
• Recognized complications requiring active surveillance include hypovolemia, acute kidney injury, pancreatic necrosis/sepsis, pulmonary compromise, and disseminated intravascular coagulation (DIC), with early detection facilitated by serial laboratory values and clinical parameter trends.

Acute pancreatitis in dogs spans a clinical spectrum from mild, self-limiting gastrointestinal upset to fulminant systemic inflammatory disease with multiple organ dysfunction. This article provides a framework for severity assessment and supportive treatment in the canine patient, written for the practicing veterinarian who must make rapid triage and monitoring decisions. The focus is on the first days of hospitalization: fluid resuscitation, analgesia, nutritional intervention, and the physiologic rationale behind each choice. Chronic pancreatitis, pancreatic abscessation requiring surgical drainage, and long-term exocrine insufficiency are outside this article's scope.

The central clinical question is which patients will progress to severe disease and which will recover with routine supportive care. Clinical judgment alone is unreliable in the first 24 hours, because the degree of pancreatic injury does not always correlate with the intensity of systemic inflammation. A structured approach to severity scoring, combined with serial reassessment of perfusion, coagulation, and renal function, allows the clinician to escalate or de-escalate therapy deliberately instead of reactively.

At a Glance

Pathophysiology of Severity Progression

The initiating event in acute pancreatitis is premature activation of trypsinogen within pancreatic acinar cells, triggering autodigestion of the gland. This fundamental mechanism is consistent across species and experimental models, as summarized in reviews of acute pancreatitis animal models and basic research. The local injury then recruits inflammatory cells, particularly macrophages, which infiltrate the pancreas and perpetuate protease activation through cathepsin B mediated pathways. Experimental work in mice has demonstrated that macrophage endocytosis of trypsinogen increases pancreatitis severity, establishing a feed-forward loop between local inflammation and systemic spread.

The transition from pancreatic inflammation to systemic disease is mediated by endothelial injury and microvascular dysfunction. Endothelial activation increases vascular permeability, promotes leukocyte migration, and disrupts normal vasomotor tone. These changes, together with coagulation system activation, account for the organ failure seen in severe disease. Laboratory markers of this process, particularly D-dimer and angiopoietin-2, have shown promise in early prediction of severe pancreatitis in human patients, as detailed in reviews of inflammation, coagulation, and endothelial injury in acute pancreatitis. The clinical implication for canine patients is that coagulation testing belongs in the initial database, not as an afterthought once bleeding develops.

The Role of Cytokine Signaling

Tumor necrosis factor alpha is a central amplifier of the systemic inflammatory response in acute pancreatitis. It upregulates adhesion molecules, primes neutrophils, and stimulates secondary cytokine cascades that drive end-organ dysfunction. Blood TNF-alpha concentrations correlate with severity in human patients, but the cytokine is cleared rapidly from circulation, limiting its practical use as a prognostic test to the first days of illness. The biological basis and clinical evidence for TNF-alpha in acute pancreatitis illustrate both the therapeutic promise of cytokine modulation and the difficulty of translating laboratory success into clinical practice. Anti-inflammatory strategies that work in controlled animal models, such as interleukin-10 administration in lethal experimental pancreatitis, have not translated into routine veterinary therapy, and the clinician should not expect cytokine-directed drugs to replace supportive care.

Severity Assessment Frameworks

No single canine-specific severity scoring system has achieved universal acceptance, and the clinician should combine multiple data streams instead of rely on one index. The approach recommended here follows the structure of ACVIM consensus statements on internal medicine conditions, which emphasize serial assessment over single-point scoring.

Clinical and Clinicopathologic Markers

Admission findings that predict severe disease include marked leukocytosis or leukopenia, azotemia, hyperglycemia, and hypocalcemia. Coagulation abnormalities, particularly elevated D-dimer, indicate endothelial injury and portend a complicated course. The presence of systemic inflammatory response syndrome criteria, defined as abnormalities in temperature, heart rate, respiratory rate, or leukocyte count, identifies patients who require intensive monitoring even when pancreatic imaging appears unremarkable.

Imaging-Based Assessment

Abdominal ultrasound provides information about pancreatic parenchymal changes, peripancreatic fat necrosis, and peritoneal effusion. The absence of ultrasonographic lesions does not exclude pancreatitis, and the presence of severe changes does not always predict outcome. Serial ultrasound examinations are more informative than a single study, particularly for detecting abscess formation or biliary obstruction that would alter management.

Fluid Therapy and Hemodynamic Support

The rationale for aggressive fluid therapy rests on the pathophysiology of endothelial leak and third-space losses. Increased vascular permeability allows protein-rich fluid to escape into the peritoneal cavity and pancreatic interstitium, reducing effective circulating volume. The goal of fluid therapy is to restore perfusion without exacerbating edema formation. Crystalloid solutions remain the first-line choice, with colloid administration reserved for patients with hypoalbuminemia or refractory hypotension.

Monitoring Resuscitation Endpoints

Perfusion parameters, including mucous membrane color, capillary refill time, heart rate, and blood pressure, should be reassessed frequently during the initial resuscitation period. Urine output, measured via urinary catheterization in severely affected patients, provides an objective endpoint that reflects renal perfusion. Lactate clearance, measured at admission and again after several hours of fluid therapy, offers a more sensitive indicator of tissue oxygenation than vital signs alone. The clinician should be cautious about over-resuscitation, because excessive fluid administration can worsen pulmonary edema and abdominal compartment physiology in patients with severe capillary leak.

Analgesia and Anti-Inflammatory Considerations

Pain control is both a humane necessity and a physiologic intervention. Uncontrolled pain increases catecholamine release, which worsens pancreatic ischemia and perpetuates the inflammatory cycle. Opioid analgesics are the mainstay of initial therapy, with multimodal approaches added when pain scores remain elevated. The choice of analgesic should be documented in the medical record, and pain scores should be reassessed at regular intervals to guide dose adjustments.

Nonsteroidal anti-inflammatory drugs are generally avoided in acute pancreatitis because of concerns about renal perfusion and gastrointestinal injury. Corticosteroids have no proven role in routine canine pancreatitis management. The MSD Veterinary Manual provides additional guidance on analgesic selection and contraindications in gastrointestinal disease, and the clinician should consult current formulary references for specific drug choices and dosing.

Nutritional Support

The historical practice of pancreatic rest, withholding food until amylase and lipase normalize, has been abandoned in favor of early enteral nutrition. The exocrine pancreas becomes resistant to cholecystokinin stimulation during acute pancreatitis, as demonstrated in experimental models where stimulated secretion is nearly abolished at the time of maximal histologic damage. This physiologic finding means that enteral feeding does not meaningfully increase pancreatic enzyme secretion during the acute phase, and the benefits of maintaining gut barrier integrity outweigh theoretical concerns about stimulating the inflamed gland.

Route and Timing of Feeding

Patients that are not vomiting and have no ultrasonographic evidence of gastric outflow obstruction can be offered small meals of a low-fat diet within 24 to 48 hours of admission. Patients that continue to vomit or refuse food should receive enteral nutrition via nasoesophageal or esophagostomy tube. Parenteral nutrition is reserved for patients that cannot tolerate any enteral route, because it does not provide the trophic effects on intestinal mucosa that enteral feeding confers. The decision to place a feeding tube should be made early in hospitalization instead of after several days of unsuccessful oral feeding attempts.

Severity Scoring in Clinical Practice

Several scoring systems have been adapted from human medicine or developed for veterinary use. The most clinically useful systems combine historical factors, physical examination findings, and serial laboratory values. No single system outperforms clinical judgment, but scoring tools provide structure and improve consistency across clinicians and over time.

The canine pancreatic-specific lipase (cPL) concentration confirms pancreatic inflammation but does not reliably predict severity. Severity prediction relies instead on markers of systemic involvement. The MSD Veterinary Manual describes acute pancreatitis as ranging from mild, self-limiting disease to a severe, life-threatening systemic inflammatory process, and this range drives the need for early risk stratification.

Practical Scoring Approaches

A practical approach assigns points for each abnormal category. Patients with three or more severe features warrant intensive care, continuous monitoring, and more aggressive intervention. Patients with fewer than three severe features may still deteriorate, so repeat assessment every 12 to 24 hours is appropriate.

Laboratory-Based Severity Markers

Serial measurement of packed cell volume, lactate, and blood glucose provides objective data on perfusion and metabolic status. Rising lactate despite fluid therapy indicates inadequate tissue perfusion or ongoing ischemia. Persistent hyperglycemia reflects stress response and impaired insulin secretion, both common in severe disease.

Coagulation assessment deserves specific attention. The interplay between inflammation and coagulation in acute pancreatitis is well documented, with endothelial injury and activation of coagulation occurring early in the disease course Institutional review of inflammation, coagulation, and endothelial injury in acute pancreatitis. A point-of-care coagulation panel or viscoelastic testing identifies patients at risk for disseminated intravascular coagulation. D-dimer elevation may precede overt clinical deterioration, although its specificity is limited in dogs with concurrent inflammatory disease.

Treatment Algorithm Overview

Treatment follows a staged approach that escalates based on severity assessment. All patients receive baseline supportive care. Patients with severe features receive additional interventions and more intensive monitoring.

Stage 1: Mild Disease

Patients with mild disease, defined as stable vital parameters, normal mentation, and no evidence of organ dysfunction, receive:

• Judicious fluid therapy to correct dehydration
• Analgesia as needed
• Early nutritional support
• Anti-emetic therapy if vomiting

These patients may be managed as outpatients if the owner can administer medications and monitor for deterioration. Hospitalization is preferred when there is any doubt about owner compliance or disease trajectory.

Stage 2: Moderate Disease

Patients with moderate disease show tachycardia, mild dehydration, or early laboratory abnormalities. These patients require hospitalization, intravenous fluid therapy, and serial monitoring. Nutritional support should begin within 24 hours of presentation if the patient tolerates enteral feeding.

Stage 3: Severe Disease

Patients with severe disease show hemodynamic instability, organ dysfunction, or coagulopathy. These patients require intensive care with:

• Aggressive fluid resuscitation with frequent reassessment
• Continuous or frequent vital parameter monitoring
• Multi-organ support
• Coagulation monitoring and intervention
• Consideration of plasma transfusion if coagulopathic

The ACVIM consensus statements provide structured guidance on diagnosis and management of internal medicine conditions, and clinicians should consult these resources when managing complex pancreatitis cases.

Fluid Therapy Selection and Adjustment

Crystalloid solutions remain the first-line choice for volume resuscitation. Balanced isotonic crystalloids are preferred over 0.9% sodium chloride because they better approximate extracellular fluid composition and avoid hyperchloremic metabolic acidosis.

Colloid therapy is reserved for patients with hypoalbuminemia or those who remain hypoperfused despite adequate crystalloid resuscitation. Synthetic colloids carry risks of coagulopathy and renal injury, so their use requires careful patient selection and monitoring.

Monitoring Fluid Therapy

Serial assessment of perfusion parameters guides fluid therapy adjustment. Heart rate, mucous membrane color, capillary refill time, pulse quality, and urine output should be assessed every 1 to 2 hours during the resuscitation phase. Body weight should be monitored every 6 to 12 hours to detect fluid overload.

Central venous pressure monitoring is useful in patients with suspected cardiac disease or those receiving large-volume resuscitation. Lactate clearance, measured 6 to 12 hours after initiating therapy, provides objective evidence of improved perfusion.

Analgesia Selection and Dosing Strategy

Pain management is a core component of pancreatitis treatment. Opioids remain the mainstay of analgesia in canine pancreatitis. Full mu-agonists such as methadone or hydromorphone provide reliable visceral analgesia. Partial agonists such as buprenorphine may be adequate for mild pain but are insufficient for moderate to severe pain.

Multimodal analgesia is appropriate in patients with significant pain. Adding a constant rate infusion of lidocaine or ketamine may reduce opioid requirements and improve pain control. Non-steroidal anti-inflammatory drugs are generally avoided in the acute phase due to concerns about renal perfusion and gastrointestinal injury, particularly in patients with vomiting or dehydration.

The MSD Veterinary Manual notes that analgesic requirements vary with disease severity, and clinicians should reassess pain scores regularly and adjust therapy accordingly.

Anti-Emetic and Gastrointestinal Support

Vomiting is common in canine pancreatitis and contributes to fluid loss, electrolyte disturbances, and aspiration risk. Maropitant, a neurokinin-1 receptor antagonist, is the first-line anti-emetic in most cases. It provides both central and peripheral anti-emetic effects and has some visceral analgesic properties.

Ondansetron or dolasetron may be added for refractory vomiting, particularly when the vomiting is thought to have a vagal or intestinal component. Metoclopramide is less useful in pancreatitis because it increases gastrointestinal motility, which may exacerbate pain.

Gastroprotectant therapy is not routinely indicated unless the patient has evidence of gastrointestinal ulceration, is receiving corticosteroids, or has a history of gastric disease.

Nutritional Support in the Treatment Algorithm

Nutritional support is no longer delayed in canine pancreatitis. Early enteral nutrition, defined as feeding within 24 to 48 hours of presentation, is associated with improved outcomes compared with delayed feeding. The ACVIM consensus statements support early nutritional intervention in critically ill patients, and pancreatitis is no exception.

Feeding Route Selection

A low-fat, highly digestible diet is appropriate for most dogs. Patients with concurrent conditions such as hyperlipidemia or inflammatory bowel disease may require specialized diets, and consultation with a veterinary nutritionist is appropriate in refractory cases.

Feeding Protocol

Continuous rate infusion feeding is better tolerated than bolus feeding in the acute phase. Start at a low rate and gradually increase over 24 to 48 hours to meet resting energy requirements. Refeeding syndrome is uncommon in dogs but can occur in severely malnourished patients, so electrolyte monitoring is appropriate during the transition to enteral feeding.

Monitoring Parameters and Documentation

Serial documentation of vital parameters, pain scores, fluid balance, and laboratory values is essential for tracking disease progression and response to therapy. A standardized monitoring sheet improves consistency and facilitates communication between shifts.

Minimum Monitoring Parameters

• Vital parameters every 4 hours in stable patients, every 1 to 2 hours in unstable patients
• Pain score every 4 hours and before each analgesic administration
• Body weight every 12 hours
• Urine output every 4 to 6 hours
• Packed cell volume and total solids every 6 to 12 hours during resuscitation
• Blood glucose every 6 to 12 hours
• Electrolytes every 12 to 24 hours
• Renal parameters every 24 hours or more frequently if azotemia is present

Documentation should include the severity score at admission, the treatment stage, and the response to each intervention. This record supports clinical decision-making and provides a basis for adjusting therapy as the disease evolves.

Recognized Complications and Early Detection

Severe canine acute pancreatitis follows a predictable trajectory of systemic involvement. The earliest detectable failure mode is endothelial injury with increased vascular permeability, which precedes overt organ dysfunction. In the early phase, activation of coagulation and endothelial damage are closely linked, and markers of these processes may identify patients destined for severe disease before clinical deterioration becomes obvious. D-dimer and angiopedietin-2 measurements appear most useful for early prediction of severe disease in human patients, and the same pathophysiologic rationale applies to dogs.

The complications that demand active surveillance are:

• Hypovolemia and hypoperfusion. Third-space fluid losses into the peritoneal cavity and gastrointestinal tract can be substantial. Serial assessment of perfusion parameters, not a single measurement, detects the trend.
• Acute kidney injury. Prerenal azotemia progresses to intrinsic renal damage when perfusion is not restored. Urine output and serial creatinine measurements discriminate between the two.
• Pancreatic necrosis and peripancreatic sepsis. Necrotic tissue becomes a nidus for bacterial translocation. Worsening fever, progressive leukocytosis, or a degenerative left shift despite supportive care should prompt evaluation for septic complications.
• Pulmonary compromise. Systemic inflammation increases capillary permeability in the lungs. Pulse oximetry and respiratory rate trends identify early hypoxemia before auscultatory changes appear.
• Disseminated intravascular coagulation. The interplay between inflammation and coagulation can tip into consumptive coagulopathy. Petechiation, prolonged clotting times, or thrombocytopenia on serial blood work warrant intervention.
• Iatrogenic complications. Overzealous fluid therapy can produce volume overload, particularly in patients with concurrent cardiac or renal disease. Rechecking perfusion after each fluid bolus, instead of following a fixed protocol, prevents this error.

Common Errors and Corrective Actions

Less experienced clinicians tend to anchor on the diagnosis and then treat the laboratory values instead of the patient. Serum lipase activity does not correlate with severity, and a declining lipase does not indicate clinical improvement. The patient's perfusion status, pain score, and ability to tolerate enteral nutrition are the meaningful endpoints.

A second recurring error is withholding analgesia out of concern that opioids will exacerbate vomiting or ileus. The exocrine pancreas becomes resistant to cholecystokinin stimulation after the onset of pancreatitis, so concerns about stimulation of secretion are not a valid reason to withhold opioids. Pain itself impairs perfusion and delays recovery.

A third error is delaying enteral nutrition until the patient has been nil per os for several days. The historical practice of pancreatic rest has been replaced by early enteral feeding, and prolonged fasting is associated with worse outcomes. If the patient cannot tolerate oral feeding, an esophagostomy or nasoenteric tube should be placed instead of continuing to fast the patient.

A fourth error is failing to escalate monitoring when the patient deteriorates. A patient who was stable for 12 hours can decompensate rapidly. Rechecking a limited panel, including packed cell volume, total solids, glucose, lactate, and electrolytes, every 6 to 8 hours in moderate to severe disease is appropriate.

Limitations of the Evidence and Areas of Disagreement

The evidence base for canine acute pancreatitis is extrapolated heavily from human medicine and experimental animal models. None of the available animal models fully replicate the clinical spectrum of severity seen in dogs, and findings from rodent models have not consistently translated to clinical benefit. The role of specific cytokine targets, including tumor necrosis factor-alpha, remains experimentally promising but clinically unproven. Blood concentrations of TNF-alpha are rapidly cleared, limiting their prognostic utility to the first days of disease, and therapeutic blockade has produced divergent results in sepsis trials.

Expert opinion still differs on several practical points. The optimal fluid rate for resuscitation in pancreatitis is debated, with some clinicians favouring aggressive crystalloid administration and others advocating a more conservative approach with colloid support. The role of synthetic colloids has been questioned in recent years. The timing and route of enteral nutrition is another area of ongoing discussion, although the consensus now favours early feeding. The value of routine antibiotic prophylaxis is contested, with most authorities reserving antibiotics for documented infection. These areas are best approached with reference to current consensus statements from professional bodies such as the American College of Veterinary Internal Medicine.

Referral and Escalation Criteria

Referral to a specialty hospital is warranted when the patient fails to stabilize within 24 to 48 hours of appropriate supportive care, when continuous rate infusion of analgesics is required but cannot be safely delivered, when the patient requires parenteral nutrition because enteral access cannot be established, or when complications such as acute kidney injury, peritonitis, or suspected pancreatic necrosis develop. Patients with suspected septic complications benefit from advanced imaging and, potentially, surgical or interventional drainage, which requires specialist facilities.

Laboratory involvement is indicated when serial monitoring reveals unexplained coagulopathy, when blood cultures are needed to guide antibiotic selection, or when the diagnosis remains uncertain despite routine testing. Regulatory reporting is rarely relevant to spontaneous canine pancreatitis, but clinicians should be aware that any suspicion of a foreign body or toxic cause may carry reporting obligations depending on jurisdiction. Consultation with a veterinary nutritionist is appropriate when the patient has comorbidities that complicate feeding, such as diabetes mellitus or hyperlipidemia, or when the patient fails to tolerate standard enteral formulas.

Frequently Asked Questions

How Do I Manage Pancreatitis When Advanced Imaging or 24-Hour Care Is Unavailable?

When computed tomography or continuous monitoring is not accessible, severity assessment relies on serial clinical examination, clinicopathologic trends, and response to initial resuscitation. Repeat point-of-care lactate, packed cell volume, total solids, and glucose measurements every 6 to 12 hours provide objective trajectories. Ultrasound, even with limited expertise, can identify pancreatic enlargement, peripancreatic effusion, and biliary obstruction. If the patient deteriorates despite fluid therapy and analgesia, or if refractory hypotension, progressive azotemia, or worsening respiratory effort develops, transfer to a facility with intensive care capacity. Document the limitations of your monitoring capability in the medical record and communicate escalation criteria to the owner before overnight hours.

What Is the Minimum Monitoring Protocol for an Outpatient or Day-Care Pancreatitis Case?

Outpatient management is appropriate only for mild disease with stable hydration, controlled vomiting, and reliable owners. Recheck the patient at 24 hours, then every 48 hours until clinical resolution. Each visit should include body weight, temperature, pain score, hydration assessment, packed cell volume, total solids, and glucose. Repeat lipase activity only if the initial diagnosis was uncertain or if clinical deterioration occurs. Instruct owners to monitor for lethargy, vomiting frequency, abdominal splinting, and reduced urine output. Provide a written escalation plan with specific triggers for re-presentation. Cases that fail to improve within 72 hours require inpatient care or referral, as persistent inflammation increases the risk of systemic complications.

How Should I Discuss Prognosis and Treatment Costs With an Owner Without Overstating Certainty?

Frame the conversation around severity category instead of a precise outcome. Explain that mild disease carries a good prognosis with supportive care, while severe disease with organ dysfunction carries substantial risk. Use the patient's own clinical trajectory to illustrate the uncertainty: improvement within 48 hours is encouraging, whereas worsening organ function warrants guarded language. Provide a cost estimate broken into phases, such as initial stabilization, daily hospitalization, and potential escalation to referral. Avoid guaranteeing survival or cure. Offer the option of a time-limited trial of therapy, for example 24 to 48 hours of intensive support, with reassessment of response and finances at that point. Document the discussion and the owner's decisions in the medical record.

Does the Treatment Approach Differ for a Diabetic or Otherwise Comorbid Pancreatitis Patient?

Yes. Preexisting conditions alter both risk and monitoring priorities. In diabetic patients, insulin requirements often fall during anorexia and rise again with refeeding, so glucose should be measured every 4 to 6 hours and insulin adjusted accordingly. Avoid corticosteroids for anti-inflammatory purposes in diabetic or immunosuppressed patients. In cardiac or renal disease, fluid therapy must be titrated more cautiously, with central venous pressure or serial thoracic ultrasound to detect volume overload. Hepatic comorbidity may worsen coagulopathy, so assess clotting times before any invasive procedure. The underlying pathophysiology of pancreatitis is unchanged, but the supportive plan must accommodate each comorbidity's specific failure modes.

What Should I Record in the Medical Record Beyond Vital Signs and Laboratory Results?

Document the severity score used and the variables that determined it, the fluid type, rate, and any adjustments with the reason for each change, and the analgesic plan including drug, route, and pain score before and after administration. Record feeding attempts, including the time, route, amount offered, and whether vomiting occurred. Note any complications, such as suspected transfusion reactions or catheter site infections, with the time of detection and corrective action. Include owner communications, especially discussions of prognosis, cost, and escalation criteria. This documentation supports continuity across shifts, defends clinical decisions, and provides a basis for retrospective review if the outcome is poor.

How Does Canine Pancreatitis Management Differ From Feline Pancreatitis?

Feline pancreatitis is more often chronic or low-grade, frequently coexists with cholangitis and inflammatory bowel disease, and presents with nonspecific signs such as anorexia and lethargy instead of vomiting. The severity assessment tools validated for dogs do not transfer directly to cats. Feline patients require more aggressive nutritional intervention because hepatic lipidosis develops rapidly with anorexia, and feeding tubes are often placed earlier. Analgesia choices are similar, but opioid dosing and safety profiles differ between species. Fluid therapy in cats requires attention to lower body weight and higher risk of volume overload. Consult species-specific references, such as the MSD Veterinary Manual and ACVIM consensus statements, for feline-specific guidance.

Related Clinical & Scientific Guides

• Feline Hepatic Lipidosis: Nutritional and Medical Management
• Canine Respiratory Infection: Diagnostic Approach and Treatment
• Canine Respiratory Virus: Diagnostic and Management Considerations

References and Further Reading

• The Interplay between Inflammation, Coagulation and Endothelial Injury in the Early Phase of Acute Pancreatitis: Clinical Implications.. 2017.
• Acute pancreatitis: animal models and recent advances in basic research.. 2007.
• Role of tumor necrosis factor-alpha in acute pancreatitis: from biological basis to clinical evidence.. 2007.
• Cathepsin B-Mediated Activation of Trypsinogen in Endocytosing Macrophages Increases Severity of Pancreatitis in Mice.. 2018.
• Interleukin-10 prevents death in lethal necrotizing pancreatitis in mice.. 1996.
• Pancreatic exocrine secretion in acute experimental pancreatitis.. 1990.
• ACVIM Consensus Statements. Journal of Veterinary Internal Medicine.
• MSD Veterinary Manual, Professional Edition. MSD Veterinary Manual.
• American Veterinary Medical Association Practice Resources. American Veterinary Medical Association.

Related Articles

• Canine Hyperadrenocorticism: Treatment Options and Monitoring
• Canine Vomiting: Diagnostic Approach for Pancreatitis
• Canine Acute Kidney Injury: Recognition and Management
• Canine Chronic Hepatitis: Diagnosis and Treatment Monitoring
• Canine Portosystemic Shunt: Medical and Surgical Management

This article is educational professional reference material for veterinary audiences. It is not a substitute for veterinary diagnosis, individual clinical judgment, current product labeling, or applicable regulatory requirements.